���ϳԹ�

The colony-forming unit (CFU) assay remains the only in vitro assay that provides a correlative assessment of hematopoietic stem and progenitor cell (HSPC) engraftment potential in vivo. For many years, regulatory bodies have recommended functional assessment and the CFU assay for labs working with cellular therapies or transplantable products derived from HSPCs. Recent updates from regulatory bodies such as FACT underscore the crucial role of the CFU assay in these workflows, particularly after any processing step, such as cryopreservation, that may impact the functional properties of HSPC products. <br><br> In this webinar, Selena Hallahan introduces the utility of the CFU assay for functional assessment of hematopoietic cell products and ���ϳԹ�’ comprehensive portfolio of reagents, training, and services designed to support high-performing and standardized workflows for hematopoietic cell therapy products.

Chronic insults, such as inflammation and replicative stress, impair and exhaust blood-sustaining hematopoietic stem cells (HSCs), leading to dysfunction and selection for leukemia-associated mutations. Dr. McKinney-Freeman’s laboratory is currently studying how sickle cell disease (SCD), an inherited hemolytic anemia with a large inflammatory component and increased hematopoietic demand, compromises the fidelity and function of hematopoietic stem cells (HSCs) in both mice and individuals with SCD. Mounting evidence indicates that SCD patients may experience enhanced rates of clonal hematopoiesis, as well as MDS (myelodysplastic syndrome) and AML (acute myeloid leukemia), in general, and following allogeneic HSC transplantation or autologous HSC gene therapy. Considering that these are the only curative therapies for SCD, it is important to better understand and prevent SCD-induced insults to HSCs and their microenvironment. <br><br> In this webinar, Dr. McKinney-Freeman from St. Jude Children’s Research Hospital describes, in detail, what her laboratory has learned about how SCD affects HSCs. Additionally, Dr. McKinney-Freeman is joined by Dr. Eric Norris, Account Executive, Cell Culture, ���ϳԹ� in the Q&A session.

Technical tip from our dedicated team of Product and Scientific Support specialists

Assessing the functional potency of cells for use in cell therapy research presents unique challenges. For hematopoietic stem and progenitor cells (HSPCs) in particular, potency can be measured in vitro by assessing the ability of these cells to differentiate into progenitor cells using the colony-forming unit (CFU) assay. Validating the CFU assay as a potency assay requires demonstrating its specificity, accuracy, precision, linearity, and reproducibility. Once validated, the CFU assay can assess the quality and consistency of prospective hematopoietic cell therapy products (HCTPs) at multiple stages of the processing and manufacturing workflow. <br><br> Join Dr. Colin Hammond and learn about the regulatory guidance around the potency testing of HCTPs and how to validate the CFU assay as a potency assay that can be integrated into cell therapy manufacturing workflows.

Obtaining consistent and reliable results when culturing immune cells can be challenging. Watch this webinar to discover how to obtain high yields of functional T cells, NK cells, B cells, dendritic cells, and macrophages for your research applications. The speaker, Evan Karas, also explains how to expand primary T cells without feeders or serum.

This webinar describes steps and considerations involved in translating research to the clinic.

In this webinar, Dr. Jackie Damen of ���ϳԹ� describes the effects of cryopreservation protocols on the engraftment potential of hematopoietic cells and the need for standardized potency assays, including the Colony-Forming Unit (CFU) assay, for hematopoietic cell products.